MedPath

A Multicenter, Randomized and Controlled Trial for Chang-An-Jun-Tai Granule in the Treatment of Patients With Irritable Bowel Syndrome With Diarrhea (IBS-D).

Phase 1
Conditions
Irritable bowel syndrome
Registration Number
ITMCTR1900002644
Lead Sponsor
The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

To simultaneously satisfy the following criteria:
1. Conform to the Roman IV(Rome IV) of a patient diagnosed with IBS-D and baseline IBS-SSS score > 75;
2. Aged 18 to 60 years;
3. Nearly 2 weeks no using the drugs in the treatment of IBS;
4. Nearly 2 weeks no using antibiotics or probiotics;
5. The patients volunteered to receive the drug and signed an informed consent form, and the informed consent process was in accordance with the relevant provisions of GCP.

Exclusion Criteria

Meet one of the following criteria were excluded:
1. there is explanation above the clinical symptoms of the patients with other diseases;
2. chronic esophagitis, Barrett esophagus and gastroesophageal reflux disease, peptic ulcer, gastric polyp (without resection), digestive tract tumor patients;
3. found that endoscopic gastric mucosa high grade intraepithelial neoplasia, pathological diagnosis, malignant gastrointestinal organic diseases;
4. patients with history of abdominal operation;
5. allergic or allergic to many medicines;
6. confusion, dementia, psychosis, neurosis and various serious unwilling to cooperate;
7. with serious the primary cardiovascular disease, liver disease, kidney disease, blood disease, lung disease, autoimmune diseases, or serious diseases affected the survival, such as cancer or aids;
8. pregnant and lactating women;
9. exist cognitive or other damage (such as vision, etc.) and impact on the participants completed self-report;
10. of the pharmaceutical composition ingredients allergies are; is or 4 weeks in other drug clinical trials of patients;
11. investigators have sufficient reason to believe that the participants according to current medical or psychological state is not suitable for researchers to study.

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Response rate of IBS-SSS scale;
Secondary Outcome Measures
NameTimeMethod
Intestinal flora;Metabonomics;IBS-SSS;HAD;IBS-QOL;AR response rate;
© Copyright 2025. All Rights Reserved by MedPath